Microba and Genetic Signatures to Merge via Scheme of Arrangement

Microba Life Sciences and Genetic Signatures have announced a plan to merge through a scheme of arrangement, aiming to create a combined entity with annual revenue approaching $30 million. The transaction structures Genetic as the acquirer, with Microba shareholders receiving 0.654 Genetic shares for every Microba share they hold. As a result, Microba investors will retain a 67% ownership stake in the enlarged group, reflecting the significant difference in market capitalization between the two firms, which stood at $35.8 million and $16.8 million respectively prior to the announcement.

The merger seeks to integrate complementary diagnostic portfolios, combining Genetic’s molecular testing platform with Microba’s clinical gut microbiome services. Both companies have reported recent revenue declines, with Genetic’s turnover down 7% to $14.8 million and Microba’s down 5.8% to $14.7 million in their latest financial years. The combined balance sheet holds approximately $30 million in cash, providing a liquidity buffer while the entities work to consolidate operations and reduce costs.

BCAL stake complicates approval process

Approval of the scheme requires support from shareholders representing at least 75% of the shares on issue and 50% of individual holders by number. This threshold creates a potential obstacle due to BCAL Diagnostics, which holds an 18.5% stake in Genetic Signatures. BCAL has expressed intent to remove certain directors, and while it has not explicitly opposed the merger, its significant voting power could influence the outcome if it mobilizes against the transaction or leverages its position to negotiate terms.

Combined entity targets cost savings

Management projects the merger will generate between $2.5 million and $3 million in annualized savings, primarily by eliminating duplicated corporate and listed company functions. The combined business will leverage Genetic’s hospital and reference laboratory customer base alongside Microba’s established relationships with clinician networks and pathology partners, including Sonic Healthcare and SYNLAB. This consolidation aims to improve operational efficiency and strengthen the group’s position within the Australian diagnostics market.

Stockhead notes that both stocks rose approximately 13% in morning trade following the announcement, suggesting initial market confidence in the strategic rationale. However, the deal remains subject to regulatory clearance and the critical approval of Genetic’s shareholder base, with BCAL’s stance being a key variable to monitor in the coming weeks.

Telix acquisition of ITM Group proceeds

Separately, Telix Pharmaceuticals is advancing its proposed $3.3 billion acquisition of Munich-based ITM Group, a leading manufacturer of therapeutic isotopes. The stock-based deal integrates ITM’s production capabilities, particularly its supply of lutetium-177 to Novartis for the prostate cancer therapy Pluvicto, with Telix’s development pipeline. Analysts view the merger as strategically sound, noting that ITM’s higher margins in isotope production complement Telix’s manufacturing footprint and secure access to a critical supply chain for radiopharmaceuticals.

ITM also brings its own clinical pipeline, including ITM-11 for neuroendocrine tumors, though the company faces a Complete Response Letter from the US FDA requiring additional work. Despite this regulatory hurdle, the combination is expected to create a vertically integrated radiopharmaceutical entity with enhanced global manufacturing capabilities and exposure to growing demand for therapeutic isotopes.